Thymosin Alpha-1

Overview

Thymosin Alpha-1 (Tα1) is a synthetic peptide fragment derived from prothymosin alpha, a thymic peptide involved in immune system regulation. In laboratory environments, Thymosin Alpha-1 is studied for its immunomodulatory, anti-inflammatory, and antiviral properties in preclinical models such as laboratory rodents. Researchers investigate Tα1 for its ability to enhance T-cell function, modulate cytokine production, and support host defense mechanisms.

Benefits

Recent preclinical studies suggest that Thymosin Alpha-1 may help boost immune system markers, regulate inflammation, and enhance resistance to certain infections in test subjects. Research indicates that Tα1 activates T-lymphocytes and dendritic cells, helping maintain immune surveillance and resilience in various experimental models.
Source: Garaci E, et al. Thymosin alpha1 for the treatment of immune deficiencies and viral infections. International Journal of Immunopathology and Pharmacology, 2019.

Possible Side Effects

In laboratory research, test subjects administered Thymosin Alpha-1 may display mild side effects such as temporary injection site irritation, slight flu-like responses, or mild fatigue-like behavior depending on dosage, frequency, and study duration.
Source: Garaci E, et al., Int J Immunopathol Pharmacol, 2019.

Dosage & Administration

Thymosin Alpha-1 is typically administered via subcutaneous injection under approved laboratory research protocols. Typical research dosages range from 0.5 mg to 1.6 mg per administration, delivered two to three times per week depending on the study’s objectives, test species, and experimental design.
For laboratory research use only. Not for human consumption.

Summary

Thymosin Alpha-1 is a synthetic thymic peptide developed exclusively for laboratory research investigating immune system modulation, antiviral pathways, and inflammation control in preclinical models. Research suggests it may help strengthen immune responses and reduce inflammation with mild side effects such as injection site irritation occasionally observed in test subjects. Thymosin Alpha-1 is administered by subcutaneous injection, with dosage and frequency tailored to each study’s design and species.
Strictly for research purposes only. Not for human use.